

Implantable Beta-Emitting Microspheres for Treatment of Malignant Tumors (for Indiana Only)

Policy Number: CS060IN.03
Effective Date: August 1, 2021

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	1
U.S. Food and Drug Administration	2
Policy History/Revision Information	2
Instructions for Use	2

Related Policies
None

Application

This Medical Policy only applies to the state of Indiana.

Coverage Rationale

Transarterial radioembolization (TARE) using yttrium-90 (⁹⁰Y) microspheres is proven and medically necessary in certain circumstances. For medical necessity clinical coverage criteria, refer to the InterQual® 2021, Apr. 2021 Release, CP: Procedures:

- Ablative or Transarterial Therapy, Liver [Age ≥ 18]
- Uterine Artery Embolization (UAE) [Age ≥ 18]

Click [here](#) to view the InterQual® criteria.

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
37243	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction
79445	Radiopharmaceutical therapy, by intra-arterial particulate administration

CPT® is a registered trademark of the American Medical Association

HCPCS Code	Description
S2095	Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90 microspheres

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

The FDA has approved two commercial forms of ⁹⁰Y microspheres; TheraSphere® and SIR-Spheres®. SIR-Spheres (Sirtex Medical) are resin ⁹⁰Y microspheres and are indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of floxuridine (FUdR). SIR-Spheres received FDA premarket approval (P990065) on March 5, 2002. Additional information is available at:

http://www.accessdata.fda.gov/cdrh_docs/pdf/p990065a.pdf.

TheraSphere (BTG) are glass ⁹⁰Y microspheres and are indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocellular carcinoma who can have placement of appropriately positioned hepatic arterial catheters. Glass ⁹⁰Y microspheres are approved by the FDA under the provisions of a Humanitarian Device Exemption (H980006). Additional information is available at: http://www.accessdata.fda.gov/cdrh_docs/pdf/H980006b.pdf.

The use of TheraSphere and SIR-Spheres is also regulated by the United States Nuclear Regulatory Commission (U.S. NRC), which grants a license for the use of these products. Refer to the following guidance for further information:

<http://pbadupws.nrc.gov/docs/ML1217/ML12179A353.pdf>.

Policy History/Revision Information

Date	Summary of Changes
08/01/2021	<ul style="list-style-type: none"> Routine review; no change to coverage guidelines Archived previous policy version CS060IN.02

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.